Basit öğe kaydını göster

Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)

dc.contributor.authorLonardi, Sara
dc.contributor.authorMoehler, Markus H.
dc.contributor.authorDvorkin, Mikhail
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorRyu, Min-hee
dc.contributor.authorMuntean, Alina Simona
dc.contributor.authorNechaeva, Marina
dc.contributor.authorBragagnoli, Arinilda Silva Campos
dc.contributor.authorCoskun, Hasan Senol
dc.contributor.authorGracian, Antonio Cubillo
dc.contributor.authorTakano, Toshimi
dc.contributor.authorWong, Rachel
dc.contributor.authorSafran, Howard
dc.contributor.authorVaccaro, Gina M.
dc.contributor.authorBoku, Narikazu
dc.contributor.authorConti, Ilaria
dc.contributor.authorHong, Janet
dc.contributor.authorXiong, Huiling
dc.contributor.authorTaieb, Julien
dc.contributor.authorBang, Yung-Jue
dc.date.accessioned2021-03-04T13:59:42Z
dc.date.available2021-03-04T13:59:42Z
dc.identifier.citationMoehler M. H. , Dvorkin M., Ozguroglu M., Ryu M., Muntean A. S. , Lonardi S., Nechaeva M., Bragagnoli A. S. C. , Coskun H. S. , Gracian A. C. , et al., "Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)", Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Kostarika, 23 - 25 Ocak 2020, cilt.38
dc.identifier.othervv_1032021
dc.identifier.otherav_7f3f30ee-7215-4424-ba98-586ef5c01939
dc.identifier.urihttp://hdl.handle.net/20.500.12627/86857
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectOnkoloji
dc.titleResults of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)
dc.typeBildiri
dc.contributor.department, ,
dc.identifier.volume38
dc.contributor.firstauthorID2277846


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster